» Articles » PMID: 27900045

MicroRNA-133b Inhibits the Migration and Invasion of Non Small Cell Lung Cancer Cells Via Targeting FSCN1

Overview
Journal Oncol Lett
Specialty Oncology
Date 2016 Dec 1
PMID 27900045
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNA (miR)-133b has been reported to act as a tumor suppressor in multiple types of human cancers, including non small cell lung cancer (NSCLC). However, the underlying mechanism by which miR-133b inhibits NSCLC metastasis remains largely unclear. In the present study, reverse transcription-quantitative polymerase chain reaction and western blotting were used to detect messenger RNA and protein expression. A wound healing assay and transwell assay were used to examine the cell migration and invasion. The expression level of miR-133b was found to be significantly downregulated in NSCLC cell lines compared with normal lung epithelial BEAS-2B cells. Further investigation identified fascin1 (FSCN1) as a direct target of miR-133b in NSCLC cells. The expression of FSCN1 was significantly increased in NSCLC cell lines compared with BEAS-2B cells, and its protein expression was negatively regulated by miR-133b in NSCLC A549 cells. Further investigation showed that the upregulation of miR-133b notably inhibited NSCLC cell migration and invasion, while the overexpression of FSCN1 significantly promoted NSCLC cell migration and invasion. Furthermore, the overexpression of FSCN1 reversed the suppressive effect of miR-133b overexpression on NSCLC cell migration and invasion. Accordingly, the present study suggests that miR-133b inhibits the migration and invasion of NSCLC cells via directly targeting FSCN1, and thus may be used for the treatment of NSCLC metastasis.

Citing Articles

Loss of MEG3 contributes to the enhanced migration and invasion in arsenic-induced carcinogenesis through NQO1/FSCN1 pathway.

Tu H, Zhang Z, Li J, Shi S, Costa M Am J Cancer Res. 2023; 13(6):2307-2322.

PMID: 37424815 PMC: 10326586.


An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth.

Chen F, Zhao H, Li C, Li P, Zhang Q Cell Death Discov. 2022; 8(1):293.

PMID: 35717530 PMC: 9206683. DOI: 10.1038/s41420-022-01082-6.


MicroRNA-133b expression inversely correlates with MET and can serve as an optimum predictive biomarker for patients of colorectal cancer.

Xie B, Gong N, Guo Y, Hu G Transl Cancer Res. 2022; 10(1):57-64.

PMID: 35116239 PMC: 8797913. DOI: 10.21037/tcr-20-2370.


AMPK activation by ASP4132 inhibits non-small cell lung cancer cell growth.

Xia Y, Zha J, Sang Y, Yin H, Xu G, Zhen J Cell Death Dis. 2021; 12(4):365.

PMID: 33824293 PMC: 8024326. DOI: 10.1038/s41419-021-03655-2.


The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo.

Alburquerque-Gonzalez B, Bernabe-Garcia A, Bernabe-Garcia M, Ruiz-Sanz J, Lopez-Calderon F, Gonnelli L Cancers (Basel). 2021; 13(4).

PMID: 33670655 PMC: 7921938. DOI: 10.3390/cancers13040861.


References
1.
Chen X, Wang K, Xu Z, Li S, Liu Q, Fu D . MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer Cell Int. 2014; 14:70. PMC: 4238049. DOI: 10.1186/s12935-014-0070-3. View

2.
Liu X, Yan S, Pei C, Cui Y . Decreased microRNA-132 and its function in human non-small cell lung cancer. Mol Med Rep. 2015; 11(5):3601-8. DOI: 10.3892/mmr.2015.3222. View

3.
Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

4.
Park S, Song J, Kim Y, Heo J, Kang H, Kim G . Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells. Int J Oncol. 2014; 44(3):637-46. PMC: 3928475. DOI: 10.3892/ijo.2013.2232. View

5.
Dimou A, Papadimitrakopoulou V . Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. J Pers Med. 2015; 4(3):386-401. PMC: 4263964. DOI: 10.3390/jpm4030386. View